Mulaomerović Adaleta, Halilbasić Alma, Cickusić Elmir, Zavasnik-Bergant Tina, Begić Lejla, Kos Janko
Medical Faculty, University of Tuzla, Bosnia and Herzegovina.
Cancer Lett. 2007 Apr 18;248(2):192-7. doi: 10.1016/j.canlet.2006.07.004. Epub 2006 Sep 1.
The concentration of cysteine protease inhibitor cystatin C was determined in sera from 59 patients with non-Hodgkin B-cell lymphoma using ELISA. The sera from 43 age and sex matched healthy blood donors served as controls. Cystatin C was significantly increased in sera of patients without therapy (mean 1136+/-SE 105.7ng/ml, p=0.00001) and with therapy (mean 1073+/-52ng/ml, p=0.001) compared to controls (mean 819+/-28ng/ml). The highest levels were determined in sera of patients with a relapse (mean 1680+/-196ng/ml). By using immunofluorescence staining and confocal microscopy we determined immature dendritic cells as a major population of cystatin C positive cells in affected lymph nodes. Our study reports for the first time that cystatin C is a potential marker for relapse in patients with non-Hodgkin B-cell lymphoma.
采用酶联免疫吸附测定法（ELISA）检测了59例非霍奇金B细胞淋巴瘤患者血清中半胱氨酸蛋白酶抑制剂胱抑素C的浓度。选取43例年龄和性别相匹配的健康献血者的血清作为对照。与对照组（平均819±28ng/ml）相比，未经治疗的患者血清中胱抑素C显著升高（平均1136±标准误105.7ng/ml，p = 0.00001），接受治疗的患者血清中胱抑素C也显著升高（平均1073±52ng/ml，p = 0.001）。复发患者血清中胱抑素C水平最高（平均1680±196ng/ml）。通过免疫荧光染色和共聚焦显微镜检查，我们确定未成熟树突状细胞是受累淋巴结中胱抑素C阳性细胞的主要群体。我们的研究首次报道胱抑素C是非霍奇金B细胞淋巴瘤患者复发的潜在标志物。
